Parkinson’s Disease
Parkinson’s disease is a progressive neurological disorder that primarily affects movement. It is named after Dr. James Parkinson, the physician who first described the condition in 1817. Parkinson’s disease develops as a result of the degeneration and loss of dopamine-producing cells in a region of the brain called the substantia nigra.
The exact cause of Parkinson’s disease is still unknown, but it is believed to involve a combination of genetic and environmental factors. There is currently no cure for Parkinson’s disease, but various treatment approaches aim to manage symptoms and improve quality of life. Medications, such as levodopa and dopamine agonists, can help replenish dopamine levels or mimic its effects. Physical therapy, occupational therapy, and speech therapy can assist with mobility, daily activities, and communication. In some cases, deep brain stimulation (DBS) surgery may be recommended to alleviate symptoms.
This magazine contains content which is gathered, validated, categorized, and supplied using a novel big data cyberinfrastructure technology that continually learns about Parkinson’s Disease.
-
Publication date: Feb 03, 2025 Alpha-synuclein gene promoter (SNCA Rep1) polymorphism has been linked to ...
-
Abnormal neuronal activity in the subthalamic nucleus contributes to dysarthria in patients with Parkinson’s disease.
Publication date: Feb 03, 2025 This study investigated the subthalamic nucleus (STN) function and deep ... -
FKBP5 Inhibition Ameliorates Neurodegeneration and Motor Dysfunction in the Neuromelanin-SNCA Mouse Model of Parkinson’s Disease.
Publication date: Feb 03, 2025 Parkinson’s disease (PD) is characterized by the loss of neuromelanin ... -
Arsenic-induced mice model of Parkinson’s disease: Revealing the neurotoxicity of arsenic through mitochondrial complexes inhibition and dopaminergic neurodegeneration in the substantia nigra region of brain.
Publication date: Feb 03, 2025 The role of environmental contaminants in causing Parkinson’s disease (PD) ... -
The Roles of Functional Bacterial Amyloids in Neurological Physiology and Pathophysiology: Pros and Cons for Neurodegeneration.
Publication date: Feb 03, 2025 Bacterial biofilms, which are complex communities of microorganisms encapsulated in ... -
Transmembrane Parkinson’s Disease mutation of PINK1 leads to altered mitochondrial anchoring.
Publication date: Feb 03, 2025 Parkinson’s disease (PD) is a devastating neurodegenerative disease resulting from ... -
Magnetic susceptibility components reveal different aspects of neurodegeneration in alpha-synucleinopathies.
Publication date: Feb 04, 2025 Nigrostriatal dopaminergic degeneration in alpha-synucleinopathies is indirectly reflected by low ... -
Interaction of Squalamine with Lipid Membranes.
Publication date: Feb 04, 2025 Squalamine is an aminosterol from dogfish shark which has drawn ... -
Short-Chain Fatty Acid Aggregates Alpha-Synuclein Accumulation and Neuroinflammation via GPR43-NLRP3 Signaling Pathway in a Model Parkinson’s Disease.
Publication date: Feb 04, 2025 Parkinson’s disease (PD) is characterized by the aggregation of α-synuclein ... -
Mitophagy in Neurodegenerative Diseases: Mechanisms of Action and the Advances of Drug Discovery.
Publication date: Feb 05, 2025 Neurodegenerative diseases (NDDs), such as Parkinson’s disease (PD) and Alzheimer’s ... -
Epigenome-wide association study, meta-analysis, and multiscore profiling of whole blood in Parkinson’s disease.
Publication date: Feb 05, 2025 An increasing body of evidence indicates altered DNA methylation in ... -
CD22 modulation alleviates amyloid β-induced neuroinflammation.
Publication date: Feb 05, 2025 Neuroinflammation is a crucial driver of multiple neurodegenerative diseases, including ... -
The Alzheimer’s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study.
Publication date: Feb 05, 2025 The Alzheimer’s Association Global Biomarker Standardization Consortium conducted a blinded ... -
Motor Symptom Variability in Parkinson’s Disease: Implications for Personalized Trial Outcomes?
Publication date: Feb 05, 2025 The Movement Disorders Society Unified Parkinson Disease Rating Scale (MDS-UPDRS), ... -
Exploring the Expanded Role of Astrocytes in Primate Brain Evolution via Changes in Gene Expression.
Publication date: Feb 05, 2025 Astrocytes are a subtype of glial cells, which are non-neuronal ... -
Neuronal α-synuclein toxicity is the key driver of neurodegeneration in multiple system atrophy.
Publication date: Feb 05, 2025 Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative ... -
High-Efficiency Capture and Proteomic Analysis of Plasma-Derived Extracellular Vesicles through Affinity Purification.
Publication date: Feb 05, 2025 Plasma-derived extracellular vesicles (EVs) are promising sources of biomarkers. It ... -
Nanosensor-based imaging of realtime dopamine release in neurons derived from iPSCs of patients with Parkinson’s disease.
Publication date: Apr 01, 2025 Dopamine (DA) is an essential neuromodulator that underlies critical aspects ... -
Association of Processed Electroencephalography Derived Parameters with Postoperative Delirium in Patients with Parkinson’s Disease Undergoing Elective Neurosurgery
Publication date: Jan 30, 2025 Patients with Parkinson’s disease seem prone to developing postoperative delirium ... -
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4006896 in Healthy Participants and Participants With Parkinson’s Disease
Publication date: Feb 04, 2025 The purpose of this study is to generate evidence of ... -
Reaction and Significance of SPN-830 Approval for Parkinson Disease: Stuart Isaacson, MD, FAAN
Publication date: Feb 04, 2025 Concepts Keywords Disease Apomorphine Fda Approval February Disease Florida Fda ...